Valuation • Kardigan

Kardigan, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing precision medicines for cardiovascular diseases with high unmet medical needs. The company's business model centers on in-licensing and advancing late-stage therapeutic candidates that target the underlying pathophysiology of heart conditions, moving beyond traditional symptom management. Kardigan's pipeline includes three primary clinical-stage programs: danicamtiv, an oral cardiac myosin activator for genetic dilated cardiomyopathy (DCM); ataciguat, a soluble guanylate cyclase activator for moderate calcific aortic valve stenosis (CAVS); and tonlamarsen, an antisense oligonucleotide for acute severe hypertension (ASH). A key differentiator for Kardigan is its proprietary "Cardiac Intelligence" platform, which incorporates Prolaio's cardiovascular data collection and analytics technology. This platform utilizes artificial intelligence, FDA-cleared algorithms, and high-density patient data from wearable devices to enhance clinical study design, improve patient responder matching, and track efficacy. By integrating deep cardiovascular biology with advanced analytics, Kardigan aims to accelerate drug development and increase the probability of clinical success. The company operates primarily in the United States, with offices in Princeton, New Jersey, and South San Francisco, California. As a pre-revenue clinical-stage biotech, Kardigan relies on venture capital and public market funding to advance its pipeline toward commercialization.